In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 studyA post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV studyPhase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependentAnalysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.Presenters:Amy E. DeZern, MD, MHSAssociate ProfessorOncology and MedicineThe Johns Hopkins University School of MedicineBaltimore, MarylandSrdan Verstovsek, MD, PhDProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:http://bit.ly/3tyQ9nG

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related